NEW YORK--(EON: Enhanced Online News)--Faruqi & Faruqi, LLP, a leading national securities law firm, is
investigating potential claims against OHR Pharmaceutical, Inc. (“OHR”
or the “Company”) (NASDAQ:OHRP).

On January 4, 2018, OHR issued a press release announcing negative
results from its study evaluating the safety and efficacy of Squalamine,
the Company’s leading therapeutic candidate for improving vision
outcomes in patients suffering from ophthalmic diseases. Specifically,
patients receiving the Squalamine combination therapy failed to show
vision improvement over candidates receiving only a Lucentis monotherapy.

If you invested in OHR stock or options and would like to discuss
your legal rights, click here:www.faruqilaw.com/OHR.
There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll freeat
877-247-4292 or at 212-983-9330 or by sending an e-mail torgonnello@faruqilaw.com.

Attorney Advertising. The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (www.faruqilaw.com).
Prior results do not guarantee or predict a similar outcome with respect
to any future matter. We welcome the opportunity to discuss your
particular case. All communications will be treated in a confidential
manner.

Recent Stories

NEW YORK--(EON: Enhanced Online News)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Akers Biosciences, Inc. (“Akers Biosciences” or th... more »

NEW YORK--(EON: Enhanced Online News)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unum Group (“Unum” or the “Company”) (NYSE:UNM). I... more »